These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30969799)

  • 21. Emergence and prevention of resistance against small molecule inhibitors.
    Wodarz D; Komarova NL
    Semin Cancer Biol; 2005 Dec; 15(6):506-14. PubMed ID: 16154360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors.
    Yin A; Moes DJAR; van Hasselt JGC; Swen JJ; Guchelaar HJ
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):720-737. PubMed ID: 31250989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changing mutational and adaptive landscapes and the genesis of cancer.
    Liggett LA; DeGregori J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?
    Perez-Plasencia C; Duenas-Gonzalez A
    Mol Cancer; 2006 Jul; 5():27. PubMed ID: 16831224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of cell density and mutations in a model of multidrug resistance in solid tumors.
    Greene J; Lavi O; Gottesman MM; Levy D
    Bull Math Biol; 2014 Mar; 76(3):627-53. PubMed ID: 24553772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global analysis of a cancer model with drug resistance due to Lamarckian induction and microvesicle transfer.
    Dénes A; Marzban S; Röst G
    J Theor Biol; 2021 Oct; 527():110812. PubMed ID: 34129816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling therapy resistance via the EGFR signaling pathway.
    Plattner C; Hackl H
    FEBS J; 2019 Apr; 286(7):1284-1286. PubMed ID: 30892828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the role of phenotypic switching in cancer drug resistance.
    Gunnarsson EB; De S; Leder K; Foo J
    J Theor Biol; 2020 Apr; 490():110162. PubMed ID: 31953135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
    Liu LL; Li F; Pao W; Michor F
    PLoS One; 2015; 10(11):e0141665. PubMed ID: 26536620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice.
    Giovannetti E; Erozenci A; Smit J; Danesi R; Peters GJ
    Crit Rev Oncol Hematol; 2012 Feb; 81(2):103-22. PubMed ID: 21546262
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On drug resistance and metronomic chemotherapy: A mathematical modeling and optimal control approach.
    Ledzewicz U; Wang S; Schattler H; Andre N; Heng MA; Pasquier E
    Math Biosci Eng; 2017 Feb; 14(1):217-235. PubMed ID: 27879129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stochastic modeling of drug resistance in cancer.
    Komarova N
    J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of acquired resistance to targeted cancer therapies.
    Lackner MR; Wilson TR; Settleman J
    Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.
    Foo J; Michor F
    PLoS Comput Biol; 2009 Nov; 5(11):e1000557. PubMed ID: 19893626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.
    Cassidy T; Nichol D; Robertson-Tessi M; Craig M; Anderson ARA
    PLoS Comput Biol; 2021 Aug; 17(8):e1009348. PubMed ID: 34460809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An elementary mathematical modeling of drug resistance in cancer.
    Bao K
    Math Biosci Eng; 2020 Dec; 18(1):339-353. PubMed ID: 33525095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A mathematical model of chromosome recombination-induced drug resistance in cancer therapy.
    Yang HL; Lei JZ
    Math Biosci Eng; 2019 Aug; 16(6):7098-7111. PubMed ID: 31698605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution.
    Huang S
    Prog Biophys Mol Biol; 2012 Sep; 110(1):69-86. PubMed ID: 22579660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
    Goldie JH; Coldman AJ
    Cancer Res; 1984 Sep; 44(9):3643-53. PubMed ID: 6744284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.